11q23 translocations (t(11q23)) are recurring cytogenetic abnormalities in both acute myeloid leukemia (AML) and acute lymphoblastic leukemia, involving the same gene, ALL1 (or MLL). Mixed lineage antigen expression has been reported in these leukemias, but its frequency and clinical significance are unknown. We immunophenotyped leukemia cells from 19 adult de novo AML patients with t(11q23) by multiparameter flow cytometry. Translocations included t(6;11)(q27;q23), t(9;11) (p22;q23), t(9;11;19)(p22;q23;q13.3), t(2;11)(11;17)(q37;q11q23; q11), t(11;17)(q23;q25), t(11;19)(q23;p13.1), t(11;19)(q23;p13.3) and t(11;22)(q23;q11). FAB types were M4 and M5. The committed stem cell and myeloid antigens HLADr, CD4dim, CD11b, CD13, CD15, CD32, CD33, CD38 and CD64 were each expressed in 80-100% of cases, and the early stem cell and lymphoid antigens CD34, CD56, CD3, CD2 and CD7 in 42, 39, 16, 5 and 5%, respectively. Antigen expression frequencies did not differ from those in 443 adequately karyotyped M4 and M5 cases without t(11q23). Fifteen patients (79%) attained complete remission (CR); median CR duration and survival were 10.0 and 15.1 months. CR duration and survival did not correlate with antigen expression. In particular, patients with t(9;11) survived longer than those with other t(11q23) (median not reached vs 7.6 months; P = 0.048), but antigen expression did not differ in the two groups. Thus frequencies of lymphoid antigen expression are similar in AML with t(11q23) and in other FAB M4 and M5 cases, treatment outcome does not differ in t(11q23) cases with and without lymphoid antigen expression, and better outcome of patients with t(9;11) compared to other t(11q23) does not correlate with differences in antigen expression. Mixed lineage antigen expression is not a distinctive feature of AML with t(11q23).
Introduction
Chromosomal translocations involving band 11q23 are recurring cytogenetic abnormalities in both acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).
1,2 The same gene, variously called ALL1, MLL, HRX or Htrx1, is rearranged in both AML and ALL with 11q23 abnormalities, suggesting a similar molecular pathogenesis regardless of lineage. [3] [4] [5] [6] [7] [8] [9] Additionally, mixed lineage antigen expression has been reported in acute leukemias with 11q23 involvement, suggesting that these leukemias may arise in pluripotent stem cells with capacity for both myeloid and lymphoid differentiation. [10] [11] [12] [13] [14] [15] [16] Moreover, pluripotent stem cell involvement might provide an explanation for adverse treatment outcome. Although expression of lymphoid antigens has been reported in AML with 11q23 abnormalities, the frequency with which these antigens are expressed is not known and the relationship between their expression and treatment outcome has not been defined.
We immunophenotyped leukemia cells from 19 adult patients with de novo AML with 11q23 translocations associated with ALL1 gene rearrangements, using multiparameter flow cytometry (MFC). 17 We determined the frequency of lymphoid antigen expression in these cases, and correlated lymphoid antigen expression with treatment outcome.
Patients and methods

Patients
Nineteen adult patients with de novo AML with 11q23 chromosome translocations enrolled on a Cancer and Leukemia Group B (CALGB) prospective immunophenotyping study of adult AML (CALGB 8361) had pretreatment marrow and/or blood samples submitted to the Laboratory of Flow Cytometry at Roswell Park Cancer Institute (RPCI) for immunophenotyping by MFC over a 4-year period beginning 1 March 1991, when the laboratory became the central immunophenotyping facility for CALGB. All patients were also enrolled on a CALGB prospective karyotyping study (CALGB 8461) and were treated on CALGB treatment protocols (CALGB 8923, 9022 or 9222) ( Refs 18, 19 and unpublished, respectively) . Induction therapy in all three treatment protocols consisted of standard-dose cytarabine and daunorubicin. Post-remission therapy in CALGB 9222 consisted of either three courses of high-dose cytarabine (HDAC) (3 g/m 2 ) administered as in CALGB 8525, 20 or one course each of HDAC, cyclophosphamide and etoposide, and diaziquone and mitoxantrone, administered as in CALGB 9022. 19 Four hundred and forty three adequately karyotyped FAB M4 and M5 de novo AML cases without 11q23 translocations were also studied.
Morphologic studies
The diagnosis of AML and the assignment of FAB subtypes were based on standard morphological and cytochemical criteria. 21 All cases were centrally reviewed.
Cytogenetic analysis
Bone marrow samples were processed for cytogenetic analysis by standard techniques, using direct and short-term ALL1 gene rearrangement studies DNA extracted from cryopreserved leukemia cells by a standard isolation procedure 23 was digested with BamHI and HindIII and then size-separated by the method of Southern. 24 Southern blots were hybridized with the 859 base pair BamHI fragment (B859) from a complementary DNA subclone spanning exons 5-11 of the ALL1 gene. 25 Multiparameter flow cytometry MFC analysis was performed on bone marrow (14 patients) and blood (five patients) samples as previously described. 26 The nine three-antibody panels used for immunophenotyping by MFC included fluorescein isothiocyanate (FL)-, phycoerythrin-and either PerCP-or phycoerythrin/Cy5 (PC)-labeled antibodies to CD45, CD14 and HLADr; CD3, CD4 and CD8; CD15, CD34 and CD56; CD33, CD13 and HLADr; CD16, CD32 and CD64; CD7, CD13 and CD2; CD11b, CD13 and CD33; CD38, CD34 and HLADr; and CD33, CD13 and CD19. The antibodies used to study expression of the lymphoid antigens CD2, CD3, CD7, CD19 and CD56 consisted of PC-labeled G11 (Caltag, South San Francisco, CA, USA), FLlabeled SK7 (Becton Dickinson, San Jose, CA, USA), FL-labeled 4H9 (AMAC, Westbrook, ME, USA), PC-labeled J4-119 (AMAC) and PC-labeled NKH1 (Coulter, Hialeah, FL, USA), respectively. Cells were also labeled with identically conjugated isotype controls for each antibody, also in three-antibody panels. Binding of isotype controls was used to create gates defining specific binding.
Statistical methods
Complete remission (CR) and relapse were defined according to the criteria of the National Cancer Institute-sponsored workshop on AML. 27 CR duration was measured from the date of attainment of CR to the date of relapse; it was censored on the date that patients were last known to be in continued first CR or the date of bone marrow transplantation in first CR. Survival was measured from the date of entry onto treatment protocols to the date of death; it was censored for patients alive at last follow-up. The median follow-up for the four patients whose CR duration was censored was 22 months and that for the six patients whose survival was censored was 27 months. The Kaplan-Meier method was used to determine the distribution of CR duration and survival.
Comparisons of continuous or percentage variables were performed with the Mann-Whitney test. Discrete variables were compared between antigen expression groups defined by expression vs lack of expression of any lymphoid antigen or of CD56 or of CD34 with the Fisher exact test. The logrank test was used to analyze differences in distributions for CR duration and survival between antigen expression groups again defined by expression or lack of expression of any lymphoid antigen or of CD56 or of CD34, except when the Kaplan-Meier curves crossed, in which the case the modified Kolmogorov-Smirnov test was used. 28 The level of significance was 0.05 for all analyses, with all tests being two-sided.
Results
Cytogenetic and molecular findings
The 19 adult de novo AML patients in our series had eight different reciprocal translocations involving 11q23, including t(9;11)(p22;q23) in 10 patients and the variant t(9;11;19) (p22;q23;q13.3) in one, t(6;11)(q27;q23) in two patients, t(11;19)(q23;p13.3) in two patients, and t(2;11)(11;17) (q37;q11q23;q11), t(11;17)(q23;q25), t(11;19)(q23;p13.1) and t(11;22)(q23;q11) in one patient each (Table 1) . Translocations involving 11q23 were the sole chromosomal change in at least one clone in 12 patients, one of whom also had a related clone with an additional chromosomal abnormality. In the other seven patients, all karyotypically abnormal cells had at least one other chromosomal change in addition to the 11q23 translocation. The additional chromosomal abnormalities included +8 in three patients, and −Y, i(8)(q10), del(13)(q13q22), +19 and +8,+8,+14 in one patient each. None of these additional chromosomal changes were recognized primary abnormalities with favorable or unfavorable prognostic significance.
Nine patients had DNA available for analysis, including four with t(9;11)(p22;q23), one with t(11;19)(q23;p13.3), and the patients with t(2;11)(11;17) (q37;q11q23; q11), t(11;17)(q23;q25), t(11;19)(q23;p13.1) and t(11;22)(q23;q11). ALL1 gene rearrangements were demonstrated by Southern blot analysis in all nine (Table 1 ).
Immunophenotype
Immunophenotypes determined by MFC are shown in Table  1 , with antigens displayed in decreasing order of frequency of expression. A consistent myeloid immunophenotype was found by MFC. The committed stem cell/early myeloid antigens CD38, CD4dim and HLADr, 29, 30 the myeloid antigens CD15, CD13, CD33 and CD11b and the granulocytic and monocytic Fc receptor antigens CD32 and CD64 were each expressed in 80-100% of cases. Thus, the prevalent pattern of myeloid antigen expression was HLADr
Additional myeloid antigens expressed included the monocytic antigen CD14, present in five cases, and the granulocytic/NK cell Fc receptor antigen CD16, present in three cases, all of which also expressed CD14.
In contrast to the consistent pattern of committed stem cell and myeloid antigen expression, expression of early stem cell and lymphoid antigens was variable ( Table 1) . The early stem cell antigen CD34 was expressed in eight cases (42%), the NK lineage antigen CD56 in seven (39%), the T cell antigen CD3 in three (16%), and the T cell antigen CD2 and T lineage antigen CD7 in one case each (5%). The B cell antigen CD19 was not expressed in any of 15 cases in which it was studied. CD34 was expressed in five of the nine cases in which at least one lymphoid antigen was expressed; CD2, CD7 and/or CD56 were expressed in four additional cases without CD34 expression. Lymphoid antigens were expressed in five of 11 cases with t(9;11) or the variant t (9;11;19) and in all three cases with 19p breakpoints, but were not expressed in either of the two t(6;11) cases (Table 1 ). There were no associations between CD34 expression and specific translocations. R, rearranged; ND, not determined.
Correlation of immunophenotype with FAB type
FAB types included M4 in six patients, M5A in eight and M5B in five (Table 1 ). The HLADr
+ immunophenotype was a consistent finding irrespective of FAB type. CD34 was expressed in M4, M5A and M5B AML (three, two and three cases, respectively), but CD56, CD14 and CD16 were only expressed in M5A and M5B cases, CD2 only in M5A and CD3 only in M5B. Expression of CD56 was significantly more frequent in M5 compared to M4 cases (58 vs 0%; P = 0.04).
Frequencies of antigen-positive leukemia cells
Percentages of leukemia cells expressing each antigen in antigen-positive cases are shown in Table 2 , with antigens again shown in decreasing order of frequency of expression. The antigens which were expressed in a majority of 11q23 translocation cases, including CD38, CD4dim, CD15, CD32, CD64, HLADr, CD33, CD13 and CD11b, were generally present on most of the leukemia cells. In contrast, the less frequently expressed antigens, including CD34, CD56 and CD3, were often expressed on only a minority of cells.
Comparison of immunophenotypes in AML with and without 11q23 translocations
Antigen expression in the 19 AML cases with 11q23 translocations was compared to that in 443 adequately karyotyped CALGB cases without 11q23 translocations immunophenotyped during the same time period (Table 3 ). The HLADr
+ immunophenotype was significantly more common in cases with 11q23 translocations than in those without (P Ͻ 0.001), as was expression of CD3 (P = 0.002) and of CD56 (P = 0.004). However, only CD56 expression differed in frequency between the 11q23 translocation cases, all of which were FAB M4 and M5, and the 89 adequately karyotyped FAB M4 and M5 cases without 11q23 translocations (P = 0.045), and there were no differences in antigen expression between FAB M5 cases with and without 11q23 translocations (Table 3) . Thus the HLADr
+ immunophenotype was a common finding in FAB M4 and M5 AML and was not specific for 11q23 translocation cases. Similarly, expression of CD56 and of CD3 on the surface of leukemia cells was found in FAB M5 AML without 11q23 translocations; it was not specific for 11q23 translocation cases.
Immunophenotypes at relapse Bone marrow samples from seven patients with 11q23 translocations were also immunophenotyped by MFC at first relapse, and relapse and diagnosis immunophenotypes were compared (Table 4) . Myeloid antigen expression changed little at relapse compared to diagnosis. The HLADr
+ immunophenotype remained present at relapse in all four cases in which it had been present at diagnosis (patients 5, 14, 17 and 19). In contrast, expression of lymphoid antigens changed at relapse in five of the seven patients. CD56 was gained in one patient (patient 15) and was lost in two patients (patients 5 and 14), one of whom also gained CD2. CD2 was acquired in two additional patients (patients 8 and 17), one of whom also gained CD7, and the other of whom also lost CD3. There were no changes in CD34 expression at relapse.
Clinical and laboratory features
Clinical presentations are summarized in Table 5 . All 19 patients had de novo AML. Age range was 17-63 years, with a median of 38 years. Median pre-treatment white blood cell count was 4.3 × 10 9 /l (range 0.6-111.0 × 10 9 /l). Median percent marrow blasts was 89 (range 41-99). Extramedullary infiltration is also shown in Table 5 . The only striking finding was the presence of gingival hypertrophy in seven patients. There was no correlation between age, white blood cell count, percent marrow blasts or gingival hypertrophy and lymphoid or early stem cell antigen expression (Table 6) .
Therapy and clinical course are also summarized in Table  5 . Remission induction therapy consisted of standard-dose cytarabine and daunorubicin 18, 19 in all 19 patients. Fifteen patients achieved CR (CR rate 79%). The four patients who did not achieve CR included three who died during induction therapy and only one (patient 16) who survived induction therapy and failed to achieve CR due to resistant disease. Of note, patient 16 was also the only patient whose leukemia cells expressed CD7 (Table 1) .
All but one (patient 11) of the 15 patients who achieved CR received intensive post-CR therapy (Table 5) . Intensification regimens included HDAC in five patients, and HDAC, cyclophosphamide and etoposide, and diaziquone and mitoxantrone in eight patients. One patient underwent allogeneic bone marrow transplantation (alloBMT) in first CR. To date, 11 of the 15 patients have relapsed, with CR durations ranging between 1.3 and 26.5 months. The patient who underwent alloBMT in first CR (patient 10 in Table 4 ) remains in first CR at 14.6 months follow-up. Median CR duration for all patients who achieved CR is 10.0 months, and median survival for all patients is 15.1 months (Figure 1) .
CR duration and survival did not correlate with patient age, white blood cell counts or presence of gingival hypertrophy, nor did they correlate with expression of any lymphoid antigen, CD56 or CD34 (Table 6 ). Outcome was better for patients with t(9;11) compared to those with other 11q23 translocations, with significantly longer survival (median not reached vs 7.6 months; P = 0.048). The four patients who have WBC, white blood cell count (× 10 9 /l); EMI, extramedullary infiltration; G, gingivae; H, liver; L, lymph nodes; Sk, skin; Spl, spleen; CR, complete remission; Y, yes; N, no; D, died; CRD, CR duration; AraC, cytarabine; HDAC, high-dose cytarabine; Ida, idarubicin; Dnr, daunorubicin; VP, etoposide; Cy, cyclophosphamide; Mitox, mitoxantrone; AZQ, diazoquinine; allo, allogeneic; auto, autologous; BMT, bone marrow transplantation. a All patients received cytarabine and daunorubicin remission induction therapy. b CRD censored for life table analysis at time of alloBMT in first CR.
Table 6
Comparisons of pretreatment characteristics and treatment outcome in cases with (LAG+) and without (LAG−) expression of lymphoid antigens, CD56 and CD34
LAG+
LAG− P CD56 not relapsed to date (one of whom underwent alloBMT in first CR) all had AML with t(9;11), but the other five patients with this translocation have relapsed. The incidence of lymphoid antigen expression was similar in cases with t(9;11) and with other 11q23 translocations (45 and 50%; P = 1.0).
Discussion
We have demonstrated a consistent myeloid immunophenotype in adult AML with 11q23 translocations associated with ALL1 gene rearrangements, with expression of the committed stem cell and myeloid antigens HLADr, CD4dim, CD11b, CD13, CD15, CD32, CD33, CD38 and CD64 in almost all cases. In contrast, expression of lymphoid antigens and of CD34 was variable, and these antigens, when expressed, were generally present on only a minority of leukemia cells. Moreover, 11q23 translocation cases were all FAB M4 or M5, and expression of myeloid, stem cell and lymphoid antigens in AML cases with 11q23 translocations did not differ from their expression in FAB M4 and M5 cases without 11q23 translocations. These data refute the frequently repeated statement that leukemias with 11q23 translocations are mixed lineage leukemias, with the implication that they differ in this regard from other acute leukemias.
The 11q23 translocations in the cases of AML included in this report involved seven different partner chromosome breakpoint regions. ALL1 gene rearrangements were demonstrated in cases of AML with t(9;11)(p22;q23), t(2;11) (11;17)(q37;q11q23;q11), t(11;17)(q23;q25), t(11;19)(q23; p13.1) and t(11;19)(q23;p13.3), consistent with the previously reported findings of other laboratories. [3] [4] [5] [6] [7] [8] [9] We also demonstrated rearrangement of ALL1 in a case of AML with t(11;22)(q23;q11). This translocation has been previously shown to involve ALL1 in only one report. 31 It has also been shown not to involve bcr on chromosome 22. 31, 32 A consistent myeloid immunophenotype, HLADr
, was found in our cases of AML with reciprocal translocations of 11q23 associated with ALL1 gene rearrangements, without regard to partner chromosome breakpoint region. Moreover, additional expression of CD34 and of lymphoid antigens also generally did not correlate with partner chromosome breakpoint region. Lack of differences in immunophenotype based on partner chromosome breakpoint region is consistent with the hypothesis that leukemogenesis in AML with 11q23 translocations results from expression of a truncated ALL1 gene, creating a truncated protein consisting of the amino terminus of ALL1, rather than from formation of a fusion protein. 33 The HLADr
+ immunophenotype was a consistent finding in cases of AML with 11q23 translocations associated with ALL1 rearrangements, but was not specific for these cases, in that the immunophenotype identified in AML with 11q23 translocations did not distinguish them from FAB M4 and M5 cases without 11q23 involvement. AML with 11q23 translocations thus differs from AML with several other relatively common recurring structural cytogenetic abnormalities, including t(8;21)(q22;q22), inv(16)(p13q22) and t(15;17)(q22;q11-12), which have been reported to be associated with specific immunophenotypes. [34] [35] [36] [37] [38] [39] In addition, the immunophenotype data did not support the hypothesis that acute leukemias with 11q23 translocations arise in early stem cells and undergo biphenotypic differentiation, because neither CD34 nor lymphoid antigens were expressed in seven of 19 cases (37%), and expression of CD34 and of lymphoid antigens was not more common in 11q23 translocations cases than in M4/M5 cases without 11q23 involvement. Finally, neither myeloid, lymphoid nor early stem cell antigen expression appeared to have prognostic significance in cases of AML with 11q23 translocations.
Treatment outcome was generally poor in our de novo AML patients with 11q23 translocations associated with ALL1 rearrangements, with relatively few disease-free survivors. Our series consisted of a relatively young group of adult AML patients who were all treated since 1991 with standard-dose cytarabine and anthracycline remission induction therapy followed by intensive post-remission chemotherapy or, in one case, allogeneic bone marrow transplantation in first CR. The CR rate was 79%, with only one remission induction failure due to resistant disease. Relapses have occurred to date in 10 of 13 patients less than 60 years of age who achieved CR and received intensive post-CR chemotherapy, including all of the patients with translocations other than t(9;11). These results may be less favorable than those in similarly treated AML patients less than 60 years of age, in whom disease-free survivals of 30-45% have been reported, 19, 20 but multivariate analyses are needed before definitive conclusions can be drawn about the treatment outcome of patients with AML with 11q23 translocations compared to AML patients less than 60 years of age without this cytogenetic abnormality.
A single patient, with AML with t(9;11), underwent allogeneic bone marrow transplantation in first CR. He remains in first CR at 14.6 months. Experience with transplantation in first CR in AML patients with 11q23 translocations is very limited at the present time. Longer follow-up and analysis of results in additional patients are needed before definitive recommendations can be made with respect to transplantation.
Previous reports of the prognostic significance of 11q23 abnormalities in AML have been inconsistent. [40] [41] [42] [43] [44] [45] [46] [47] [48] Remission rates have ranged between 33 and 83% in different series. [41] [42] [43] [44] [45] [46] [47] [48] CR duration and survival have been reported as poor in most series, but as intermediate or favorable in some. [40] [41] [42] [43] [44] [45] [46] [47] [48] Likely reasons for this inconsistency are analysis of small numbers of patients, inclusion of both children and adults, and lack of uniformity of therapeutic approaches, with many patients receiving less intensive regimens than those in current use. Moreover, previous reports have generally included patients with translocations, deletions and inversions with 11q23 breakpoints, and ALL1 gene rearrangement studies have not been performed. ALL1 appears to be involved in all reciprocal translocations involving 11q23 in AML other than the t(11;17)(q23;q21) seen in FAB M3 disease, but is not involved in all chromosome 11 deletions with 11q23 breakpoints. 8, 9, [49] [50] [51] Ours is the first series restricted to patients with 11q23 translocations known to involve ALL1. CR durations were relatively brief in our series, but there are patients who have not relapsed to date, all of whom had the t(9;11).
Results of recent pediatric series suggest that children with de novo AML with the t(9;11) have a favorable outcome when treated with etoposide-containing regimens, with a high CR rate and prolonged disease-free survival, [52] [53] [54] whereas children with other 11q23 abnormalities do poorly. 52, 54 A superior treatment outcome for adult AML patients with t(9;11) compared to those with other 11q23 translocations has recently been reported by CALGB. 55 All of the disease-free survivors in our series were patients with t(9;11). Of note, however, more than half of our patients with t(9;11) have relapsed.
Treatment outcome in 11q23 translocation cases did not correlate with immunophenotype. The combination of high CR rate and short CR duration might be explained by initially drug-sensitive disease but rapid regrowth of residual disease. Variables such as drug resistance patterns and cell kinetic parameters need to be studied to explain the predominant pattern of treatment response of AML with 11q23 translocations associated with ALL1 rearrangements as well as the exceptions.
